BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22706491)

  • 1. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
    Federico V; Breccia M; Petrucci MT; Loglisci G; Mansueto G; Mercanti C; Levi A; Cartoni C; Musto P; Alimena G
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):266-8. PubMed ID: 22706491
    [No Abstract]   [Full Text] [Related]  

  • 2. A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
    Mangiacavalli S; Varettoni M; Zappasodi P; Pica G; Lazzarino M; Corso A
    Leuk Res; 2009 Apr; 33(4):577-8. PubMed ID: 18842298
    [No Abstract]   [Full Text] [Related]  

  • 3. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
    Ali R; Ozkalemkas F; Ozkan A; Ozkocaman V; Ozcelik T; Ozan U; Kurt M; Tunali A
    Leuk Res; 2007 Aug; 31(8):1153-5. PubMed ID: 16945413
    [No Abstract]   [Full Text] [Related]  

  • 4. Extramedullary involvement: an emerging problem in multiple myeloma.
    Molica S
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):268-9. PubMed ID: 22706492
    [No Abstract]   [Full Text] [Related]  

  • 5. Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
    Moriuchi M; Ohmachi K; Kojima M; Tsuboi K; Ogawa Y; Nakamura N; Ando K
    Tokai J Exp Clin Med; 2010 Apr; 35(1):17-20. PubMed ID: 21319020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of bortezomib on bone disease in multiple myeloma.
    Drake MT; Rajkumar SV
    Am J Hematol; 2009 Jan; 84(1):1-2. PubMed ID: 19030185
    [No Abstract]   [Full Text] [Related]  

  • 7. [Bortezomib in second-line therapy].
    Musch A
    Med Monatsschr Pharm; 2005 Sep; 28(9):332-3. PubMed ID: 16163891
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.
    Fröhlich K; Holle JU; Aries PM; Gross WL; Moosig F
    Ann Rheum Dis; 2011 Jul; 70(7):1344-5. PubMed ID: 21173019
    [No Abstract]   [Full Text] [Related]  

  • 9. Bortezomib therapy following first relapse.
    Orlowski RZ;
    Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
    Zangari M; Guerrero J; Cavallo F; Prasad HK; Esseltine D; Fink L
    Haematologica; 2008 Jun; 93(6):953-4. PubMed ID: 18515882
    [No Abstract]   [Full Text] [Related]  

  • 11. Bortezomib increases survival of patients with relapsed multiple myeloma.
    Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
    [No Abstract]   [Full Text] [Related]  

  • 12. Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease.
    Siniscalchi A; Dentamaro T; Perrotti A; Tatangelo P; de Fabritiis P; Caravita T
    Ann Hematol; 2010 Aug; 89(8):821-2. PubMed ID: 19953253
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
    Satoh M; Oguro R; Yamanaka C; Takada K; Matsuura Y; Akiba T; Aotsuka N; Tani Y; Wakita H
    J Pharm Pharm Sci; 2011; 14(1):78-89. PubMed ID: 21501555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib in multiple myeloma.
    Vandenbroucke JP; Kroep JR
    N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16180272
    [No Abstract]   [Full Text] [Related]  

  • 15. Unusual discordant responses in two multiple myeloma patients during bortezomib treatment.
    Pirrotta MT; Gozzetti A; Cerase A; Bucalossi A; Bocchia M; Defina M; Lauria F
    Onkologie; 2008 Feb; 31(1-2):45-7. PubMed ID: 18268398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib data show improved survival in patients with relapsed multiple myeloma.
    Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202
    [No Abstract]   [Full Text] [Related]  

  • 17. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
    Mele G; Pinna S; Alloro E; Brocca MC; Coppi MR; Quarta G
    Leuk Res; 2007 May; 31(5):721-3. PubMed ID: 16890285
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib for myeloma -- much ado about something.
    Dispenzieri A
    N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811
    [No Abstract]   [Full Text] [Related]  

  • 19. Concurrent radiation therapy and bortezomib in myeloma patient.
    Berges O; Decaudin D; Servois V; Kirova YM
    Radiother Oncol; 2008 Feb; 86(2):290-2. PubMed ID: 18199515
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of intrapleural bortezomib in myelomatous pleural effusion.
    Iannitto E; Minardi V; Tripodo C
    Br J Haematol; 2007 Nov; 139(4):621-2. PubMed ID: 17979947
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.